A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Inclusion Criteria: * Patients with histologically proven T-cell angioimmunoblastic lymphoma (AIL) on lymph node biopsy. * Aged from 60 to 80 years. * Patient not previously treated (except corticosteroids providing they have been initiated less than 10 days before inclusion). * ECOG performance status 0 to 2. * With a minimum of life expectancy \> 3 months. * Negative HIV, HBV and HCV serological tests \< 4 weeks (except after vaccination). * Having previously signed a written informed consent. Exclusion Criteria: * Any other histological type of T-cell lymphoma. * Central nervous system or meningeal involvement by lymphoma. * Contra-indication to any drug included in the R-CHOP regimen. * Concurrent severe disease (according to the investigator's decision). * Active bacterial, viral or fungal infection. * Poor renal function (serum creatinine level \> 150 µmol/L) or impaired liver function tests (total bilirubin level \> 30 µmol/L, transaminases \> 2.5 upper normal limits) unless they are related to the lymphoma. * Poor bone marrow reserve as defined by neutrophils \< 1.5 x 109/L or platelets \< 100 x 109/L, unless related to bone marrow infiltration. * Any history of cancer during the last 5 years, with the exception of non basal cell carcinoma of the skin or in situ carcinoma of the cervix. * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study. * Patient under tutelage.